Correlation Between TuHURA Biosciences and Telix Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both TuHURA Biosciences and Telix Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining TuHURA Biosciences and Telix Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between TuHURA Biosciences and Telix Pharmaceuticals Limited, you can compare the effects of market volatilities on TuHURA Biosciences and Telix Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in TuHURA Biosciences with a short position of Telix Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of TuHURA Biosciences and Telix Pharmaceuticals.

Diversification Opportunities for TuHURA Biosciences and Telix Pharmaceuticals

0.16
  Correlation Coefficient

Average diversification

The 3 months correlation between TuHURA and Telix is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding TuHURA Biosciences and Telix Pharmaceuticals Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Telix Pharmaceuticals and TuHURA Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on TuHURA Biosciences are associated (or correlated) with Telix Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Telix Pharmaceuticals has no effect on the direction of TuHURA Biosciences i.e., TuHURA Biosciences and Telix Pharmaceuticals go up and down completely randomly.

Pair Corralation between TuHURA Biosciences and Telix Pharmaceuticals

Given the investment horizon of 90 days TuHURA Biosciences is expected to generate 6.02 times more return on investment than Telix Pharmaceuticals. However, TuHURA Biosciences is 6.02 times more volatile than Telix Pharmaceuticals Limited. It trades about 0.12 of its potential returns per unit of risk. Telix Pharmaceuticals Limited is currently generating about 0.16 per unit of risk. If you would invest  376.00  in TuHURA Biosciences on September 23, 2024 and sell it today you would earn a total of  72.00  from holding TuHURA Biosciences or generate 19.15% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

TuHURA Biosciences  vs.  Telix Pharmaceuticals Limited

 Performance 
       Timeline  
TuHURA Biosciences 

Risk-Adjusted Performance

1 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in TuHURA Biosciences are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, TuHURA Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.
Telix Pharmaceuticals 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Telix Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

TuHURA Biosciences and Telix Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with TuHURA Biosciences and Telix Pharmaceuticals

The main advantage of trading using opposite TuHURA Biosciences and Telix Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if TuHURA Biosciences position performs unexpectedly, Telix Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telix Pharmaceuticals will offset losses from the drop in Telix Pharmaceuticals' long position.
The idea behind TuHURA Biosciences and Telix Pharmaceuticals Limited pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bonds Directory
Find actively traded corporate debentures issued by US companies